tradingkey.logo

Insulet Corp

PODD
241.930USD
-1.220-0.50%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
17.02BMarktkapitalisierung
69.05KGV TTM

Insulet Corp

241.930
-1.220-0.50%

mehr Informationen über Insulet Corp Unternehmen

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Insulet Corp Informationen

BörsenkürzelPODD
Name des UnternehmensInsulet Corp
IPO-datumMay 15, 2007
CEOMcevoy (Ashley)
Anzahl der mitarbeiter3900
WertpapierartOrdinary Share
GeschäftsjahresendeMay 15
Addresse100 Nagog Park
StadtACTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01720-3440
Telefon19786007000
Websitehttps://www.omnipod.com
BörsenkürzelPODD
IPO-datumMay 15, 2007
CEOMcevoy (Ashley)

Führungskräfte von Insulet Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+778.00%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-1380.00%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-4263.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+778.00%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+759.00%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
3.85K
+962.00%
Mr. Prem Singh
Mr. Prem Singh
Senior Vice President - Global Operations
Senior Vice President - Global Operations
3.56K
-687.00%
Ms. Laetitia Cousin
Ms. Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
3.44K
-140.00%
Dr. Luciana Borio, M.D.
Dr. Luciana Borio, M.D.
Independent Director
Independent Director
3.09K
-481.00%
Mr. Timothy J. (Tim) Scannell
Mr. Timothy J. (Tim) Scannell
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+778.00%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-1380.00%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-4263.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+778.00%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+759.00%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
3.85K
+962.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
U.S.Omnipod
497.10M
70.38%
International Omnipod
202.10M
28.61%
Drug Delivery
7.10M
1.01%
Nach RegionUSD
Name
Umsatz
Anteil
United States
504.20M
71.39%
All Other
202.10M
28.61%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
U.S.Omnipod
497.10M
70.38%
International Omnipod
202.10M
28.61%
Drug Delivery
7.10M
1.01%

Aktionärsstatistik

Aktualisiert: Sat, Jan 10
Aktualisiert: Sat, Jan 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.32%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Andere
60.70%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.32%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Andere
60.70%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
65.60%
Investment Advisor/Hedge Fund
23.74%
Hedge Fund
4.88%
Pension Fund
2.69%
Research Firm
2.52%
Sovereign Wealth Fund
1.57%
Bank and Trust
1.15%
Individual Investor
0.30%
Family Office
0.05%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
1598
71.88M
102.17%
-3.26M
2025Q3
1546
72.07M
102.39%
-3.66M
2025Q2
1541
72.80M
103.47%
-3.81M
2025Q1
1569
72.82M
103.50%
-3.52M
2024Q4
1508
72.57M
103.34%
-4.94M
2024Q3
1436
73.14M
104.31%
-3.15M
2024Q2
1408
72.17M
103.04%
-3.02M
2024Q1
1350
71.60M
102.26%
-3.12M
2023Q4
1320
72.91M
104.42%
-1.52M
2023Q3
1254
72.05M
103.19%
-4.06M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
8.76M
12.46%
+86.58K
+1.00%
Sep 30, 2025
Fidelity Management & Research Company LLC
6.91M
9.83%
+58.10K
+0.85%
Sep 30, 2025
Capital Research Global Investors
4.55M
6.47%
-187.06K
-3.95%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.43M
6.29%
+74.83K
+1.72%
Sep 30, 2025
State Street Investment Management (US)
3.09M
4.39%
+33.93K
+1.11%
Sep 30, 2025
Baillie Gifford & Co.
2.09M
2.97%
-43.37K
-2.03%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.97M
2.79%
+37.85K
+1.96%
Sep 30, 2025
ClearBridge Investments, LLC
1.47M
2.09%
-69.39K
-4.52%
Sep 30, 2025
American Century Investment Management, Inc.
1.41M
2%
+97.19K
+7.42%
Sep 30, 2025
Fidelity International
1.11M
1.58%
-19.10K
-1.69%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Langar Global HealthTech ETF
7.26%
Innovator IBD Breakout Opportunities ETF
4.88%
Global X HealthTech ETF
4.76%
Goldman Sachs Future Health Care Equity ETF
4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.7%
iShares Health Innovation Active ETF
3%
Congress SMid Growth ETF
2.82%
iShares U.S. Medical Devices ETF
2.62%
FT Raymond James Multicap Growth Equity ETF
2.3%
Acruence Active Hedge US Equity ETF
2.27%
Mehr Anzeigen
Langar Global HealthTech ETF
Anteil7.26%
Innovator IBD Breakout Opportunities ETF
Anteil4.88%
Global X HealthTech ETF
Anteil4.76%
Goldman Sachs Future Health Care Equity ETF
Anteil4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil3.7%
iShares Health Innovation Active ETF
Anteil3%
Congress SMid Growth ETF
Anteil2.82%
iShares U.S. Medical Devices ETF
Anteil2.62%
FT Raymond James Multicap Growth Equity ETF
Anteil2.3%
Acruence Active Hedge US Equity ETF
Anteil2.27%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI